New data from the ENHANCE Ph 3b study show rapid 30-minute infusions are well tolerated in patients with #RMS. Check out the data: bit.ly/4gmEMrs – #TGTX #ECTRIMS2024 starts today #MS #FearlessForPatients
TG Therapeutics, Inc.
Biotechnology Research
New York, NY 28,149 followers
TG is a biopharmaceutical company focused on the development of novel treatments for B-cell diseases.
About us
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
- Website
-
http://www.tgtherapeutics.com/
External link for TG Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 2011
- Specialties
- Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
Locations
-
Primary
New York, NY 10014, US
Employees at TG Therapeutics, Inc.
Updates
-
New data in #RMS shows 92% of patients free from disability progression after 5 years of treatment. Check out the data: bit.ly/4e6ssKx – #TGTX #ECTRIMS2024 starts today #MS #FearlessForPatients
-
Abstracts are Live! #ECTRIMS2024 Copenhagen, Denmark Sept. 18-20. #TGTX will share 3 presentations highlighting data in #RMS. Check out the abstracts: bit.ly/4cOGSxq Please visit our TG Booth C3-B01 & Business Suite in section B5. #MS #FearlessForPatients
-
#TGTX Q2 2024 Financial Results have been released! Details: bit.ly/4fwkwmR - Join our #Earnings call this morning at 8:30AM ET. Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q2 2024 – Webcast at: https://lnkd.in/eguXMYM #FearlessForPatients
-
#TGTX will host a Q2 2024 Earnings Call on Tues., August 6, 2024 @ 8:30AM ET. Dial in: 1-877-407-8029 (US), 1-201-689-8029 (Ex-US) Title: TG Q2 2024 - Webcast will be available at: https://lnkd.in/eguXMYM #FearlessForPatients #Earnings
-
#DontMissIt - Join today’s Fireside Chat with TG CEO Mike Weiss at the Goldman Sachs 45th Annual Global Healthcare Conference 2024 - Tuesday, June 11th @ 1:20PM ET. AudioCast: https://lnkd.in/eC6nRGS #TGTX #FearlessForPatients Goldman Sachs
-
#SaveTheDate - Join the Fireside Chat with TG CEO Mike Weiss at the Goldman Sachs 45th Annual Global Healthcare Conference 2024 next Tuesday, June 11th @ 1:20PM ET. Details: bit.ly/3VtzC4u Watch: https://lnkd.in/eC6nRGS #TGTX #FearlessForPatients Goldman Sachs
-
#Reminder - Join today’s Fireside Chat with TG CEO Mike Weiss at the Jefferies Global Healthcare Conference 2024 - Wed., June 5th @ 1:30PM ET. Watch Here: https://lnkd.in/eC6nRGS #TGTX #FearlessForPatients Jefferies #JefferiesHealthcare
-
#SaveTheDate - Join the Fireside Chat with TG CEO Mike Weiss at the Jefferies Global Healthcare Conference 2024 this Wed., June 5th @ 1:30PM ET. Details: bit.ly/4aG2H16 Watch: https://lnkd.in/eC6nRGS #TGTX #FearlessForPatients Jefferies #JefferiesHealthcare
-
TG Therapeutics shared 2 presentations yesterday at #CMSC2024 Nashville highlighting post-marketing study designs in #RMS. Check out the presentations: bit.ly/4e44OhX #TGTX CMSC #FearlessForPatients